WILLIAM GEORGE NELSON, M.D.
Osteopathic Medicine at Wolfe St, Baltimore, MD
License number
Maryland D39683
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
600 N Wolfe St, Baltimore, MD 21287
Phone
(410) 955-8964
(410) 933-7400
(410) 933-7400
Personal information
See more information about WILLIAM GEORGE NELSON at radaris.comName
Address
Phone
524 Chestnut Hill Rd, Forest Hill, MD 21050
522 Chestnut Hill Rd, Forest Hill, MD 21050
5350 Wildlife Pl, Pomfret, MD 20675
5313 Liberty Heights Ave, Gwynn Oak, MD 21207
49 Stoney Point Ct, Germantown, MD 20876
Professional information
See more information about WILLIAM GEORGE NELSON at trustoria.com
William George Nelson, Baltimore MD
William George Nelson, Baltimore MD
Specialties:
Internal Medicine, Hematology & Oncology, Medical Oncology
Work:
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
401 N Broadway St, Baltimore, MD 21287 JHU Oncology
600 N Wolfe St, Baltimore, MD 21287 The Falls Concourse
10753 Falls Rd, Lutherville Timonium, MD 21093
401 N Broadway St, Baltimore, MD 21287 JHU Oncology
600 N Wolfe St, Baltimore, MD 21287 The Falls Concourse
10753 Falls Rd, Lutherville Timonium, MD 21093
Education:
Johns Hopkins University (1987)
Telecommunications Professional
Telecommunications Professional
Location:
Baltimore, Maryland Area
Industry:
Telecommunications
Methods Of Diagnosing And Treating Hepatic Cell Proliferative Disorders
Methods Of Diagnosing And Treating Hepatic Cell Proliferative Disorders
US Patent:
6709818, Mar 23, 2004
Filed:
Oct 12, 2000
Appl. No.:
09/687246
Inventors:
William G. Nelson - Towson MD
Xiaohui Lin - Baltimore MD
Julia C. Tchou - Baltimore MD
Jila Bakker - Baltimore MD
Xiaohui Lin - Baltimore MD
Julia C. Tchou - Baltimore MD
Jila Bakker - Baltimore MD
Assignee:
The Johns Hopkins University School of Medicine - Baltimore MD
International Classification:
C12Q 168
US Classification:
435 6, 435 911, 435 912, 536 231, 536 243, 536 2431, 536 2433
Abstract:
Provided are methods and compositions useful for the diagnosis, prognosis and treatment of hepatic cellular proliferative disorders. The methods include the modulation or analysis of hypemethylated glutathione-S-transferase nuleic acid sequence in hepatic samples and biological fluids.
William George Nelson, Baltimore MD
William George Nelson, Baltimore MD
Specialties:
Oncologist
Address:
600 N Wolfe St, Baltimore, MD 21287
600 N Wolfe, Baltimore, MD 21287
600 N Wolfe, Baltimore, MD 21287
Education:
Johns Hopkins University, School of Medicine - Doctor of Medicine
Johns Hopkins University - Doctor of Philosophy
Johns Hopkins Hospital - Fellowship - Oncology (Internal Medicine)
Johns Hopkins Hospital - Residency - Internal Medicine
Johns Hopkins University - Doctor of Philosophy
Johns Hopkins Hospital - Fellowship - Oncology (Internal Medicine)
Johns Hopkins Hospital - Residency - Internal Medicine
5-Hydroxymethylcytosine In Human Cancer
5-Hydroxymethylcytosine In Human Cancer
US Patent:
2014003, Feb 6, 2014
Filed:
Aug 1, 2013
Appl. No.:
13/956879
Inventors:
Michael Christoph Haffner - Baltimore MD, US
Alcides Chaux - Baltimore MD, US
William G. Nelson - Towson MD, US
Angelo M. DeMarzo - Baltimore MD, US
Alcides Chaux - Baltimore MD, US
William G. Nelson - Towson MD, US
Angelo M. DeMarzo - Baltimore MD, US
Assignee:
The Johns Hopkins University - Baltimore MD
International Classification:
G01N 33/574
US Classification:
435 611
Abstract:
The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for diagnosing or predicting cancer in a patient. In one embodiment, a method for identifying a patient as having cancer comprises the steps of (a) providing a formalin-fixed, paraffin-embedded or fresh frozen sample of patient tissue; (b) steaming the sample in antigen retrieval buffer; (c) incubating the sample in hydrochloric acid (HCl); (d) incubating the sample with an affinity reagent specific for 5hmC under conditions to form a complex between the affinity reagent and 5-hydroxymethylcytosine (5hmC) present in the sample; (e) detecting the complexes formed between 5hmC and the affinity reagent with secondary detection reagents; (f) quantifying 5hmC levels; and (g) identifying the patient as having cancer if the 5hmC levels in the sample are reduced as compared to a control.
Method Of Enriching Rare Cells
Method Of Enriching Rare Cells
US Patent:
5962237, Oct 5, 1999
Filed:
Apr 2, 1997
Appl. No.:
8/832468
Inventors:
Paul O. P. Ts'o - Ellicott City MD
Stephen A. Lesko - Baltimore MD
William G. Nelson - Towson MD
Alan W. Partin - Baltimore MD
Stephen A. Lesko - Baltimore MD
William G. Nelson - Towson MD
Alan W. Partin - Baltimore MD
Assignee:
The Johns Hopkins University School of Medicine - Baltimore MD
International Classification:
G01N 33574, G01N 3353, G01N 930, B01D 3315
US Classification:
435 723
Abstract:
A method for enriching cancer cells such as prostate cancer cells in a bodily fluid sample is disclosed comprising (a) obtaining the sample comprising cancer cells and non-rare cells; (b) subjecting the sample to multiple density gradient separation comprising a first density gradient and a second density gradient, wherein the second density gradient is greater than the first density gradient, and producing a first fluid comprising an increased concentration of cancer cells of a first density, and a second fluid comprising an increased concentration of cancer cells of a second density, wherein the second density is greater than the first density; wherein subjecting the sample to multiple density gradient separation includes producing a plasma layer, a first interface layer, a first gradient layer, a second interface layer, a second gradient layer, and a cell pellet; wherein producing the first fluid includes combining the first interface layer and the first gradient layer and forming a first suspension; and wherein producing the second fluid includes combining the second interface layer and the second gradient layer and forming a second suspension; (c) subjecting said second fluid comprising the second suspension to a binding agent that binds non-rare cells; and (d) removing the bound non-rare cells from the second fluid to provide a second fluid enriched with the greater density cancer cells.
Cancer-Associated Antigens And Methods Of Their Identification And Use
Cancer-Associated Antigens And Methods Of Their Identification And Use
US Patent:
7226606, Jun 5, 2007
Filed:
Nov 16, 2005
Appl. No.:
11/274856
Inventors:
James McArthur - San Carlos CA, US
Dale Ando - Walnut Creek CA, US
Margo Roberts - Charlottesville VA, US
Jonathan Simons - Atlanta GA, US
William Nelson - Towson MD, US
Dale Ando - Walnut Creek CA, US
Margo Roberts - Charlottesville VA, US
Jonathan Simons - Atlanta GA, US
William Nelson - Towson MD, US
Assignee:
Cell Genesys, Inc. - South San Francisco CA
International Classification:
A61K 35/12
US Classification:
4242771, 424 933, 435371
Abstract:
The present invention provides novel, isolated, tumor-associated antigens, and methods for identifying such antigens in a biological sample, and of screening for the presence of such an antigen in a biological specimen, wherein the tumor antigen identified reacts with serum from a subject treated with a vaccine comprising a cytokine and proliferation-incompetent tumor cells which express the tumor-associated antigen. Also provided are kits for carrying out the methods of the invention.
Methods Of Diagnosing And Treating Hepatic Cell Proliferative Disorders
Methods Of Diagnosing And Treating Hepatic Cell Proliferative Disorders
US Patent:
2005002, Feb 3, 2005
Filed:
Sep 15, 2003
Appl. No.:
10/663189
Inventors:
William Nelson - Towson MD, US
Xiaohui Lin - Baltimore MD, US
Julia Tchou - Baltimore MD, US
Jila Bakker - Baltimore MD, US
Xiaohui Lin - Baltimore MD, US
Julia Tchou - Baltimore MD, US
Jila Bakker - Baltimore MD, US
International Classification:
C12Q001/68, C12P019/34
US Classification:
435006000, 435091200
Abstract:
Provided are methods and compositions useful for the diagnosis, prognosis and treatment of hepatic cellular proliferative disorders. The methods include the modulation or analysis of hypemethylated glutathione-S-transferase nuleic acid sequence in hepatic samples and biological fluids.
Cancer-Associated Antigens And Methods Of Their Identification And Use
Cancer-Associated Antigens And Methods Of Their Identification And Use
US Patent:
7645587, Jan 12, 2010
Filed:
May 2, 2007
Appl. No.:
11/799584
Inventors:
James McArthur - San Carlos CA, US
Dale Ando - Walnut Creek CA, US
Margo Roberts - Charlottesville VA, US
Jonathan Simons - Baltimore MD, US
William Nelson - Towson MD, US
Dale Ando - Walnut Creek CA, US
Margo Roberts - Charlottesville VA, US
Jonathan Simons - Baltimore MD, US
William Nelson - Towson MD, US
Assignee:
BioSante Pharmaceuticals, Inc. - Lincolnshire IL
John Hopkins University - Baltimore MD
John Hopkins University - Baltimore MD
International Classification:
G01N 33/53
US Classification:
435 71
Abstract:
The present invention provides novel, isolated, tumor-associated antigens, and methods for identifying such antigens in a biological sample, and of screening for the presence of such an antigen in a biological specimen, wherein the tumor antigen identified reacts with serum from a subject treated with a vaccine comprising a cytokine and proliferation-incompetent tumor cells which express the tumor-associated antigen. Also provided are kits for carrying out the methods of the invention.
Agents For Reversing Epigenetic Silencing Of Genes
Agents For Reversing Epigenetic Silencing Of Genes
US Patent:
2010009, Apr 15, 2010
Filed:
Dec 21, 2007
Appl. No.:
12/521109
Inventors:
William G. Nelson - Towson MD, US
Srinivasan Yegnasubramanian - Baltimore MD, US
Xiaohui Lin - Redlands CA, US
Traci J. Speed - Baltimore MD, US
Zachery Reichert - Baltimore MD, US
Srinivasan Yegnasubramanian - Baltimore MD, US
Xiaohui Lin - Redlands CA, US
Traci J. Speed - Baltimore MD, US
Zachery Reichert - Baltimore MD, US
International Classification:
A61K 31/52, C12Q 1/68, A61K 31/4402, A61K 31/517, A61K 31/4164, A61K 31/341, A61K 31/40, A61K 31/415, A61K 31/4155, A61P 35/00, A61P 7/00
US Classification:
5142632, 435 6, 514333, 514342, 51426631, 514393, 514470, 514414, 514361, 514403
Abstract:
The present invention provides methods for discovering agents that are effective in reversing epigenetic silencing by inhibiting the interaction of methyl-binding (MBD) proteins with methylated genomic DNA. Also provided are methods for reactivating silenced genes having CpG island hypermethylation along with methods for treatment and prevention of diseases, such as cancer and sickle cell anemia, by administering an agent that modulates methyl-binding domain (MBD) protein-mediated transcriptional repression, thereby increasing gene transcription to prevent or treat disease. Additionally, compounds identified by the present invention useful for treatment and prevention of diseases, such as cancer and sickle cell anemia, are provided.